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1University of York,York, UK, 2York Health Economics Consortium,
York, North Yorkshire, UK
OBJECTIVES: Delayed healing of a tibial fracture is likely to
cause substantial impairment to the patient’s quality of life, as
well as increasing the risk of complications. This study estimates
the total costs of using Exogen, an ultrasound device designed
to expedite the healing process, in addition to current practice.
METHODS: An economic model was designed in order to esti-
mate the costs and outcomes of each treatment. The model com-
pared Exogen against conservative treatment (i.e. plaster cast),
and also considered the cost impact of using Exogen to augment
patients who underwent surgery. Resource use for each stage in
the pathway was multiplied by the unit cost of that resource.
Effectiveness data were drawn from published sources. Cost data
were derived from existing national databases, whilst resource
use data were based on interviews with clinical experts. The per-
spective is that of the National Health Service (NHS). RESULTS:
Exogen is expected to be cost saving for patients with a fresh
tibial fracture who are at risk of delayed healing or non-union.
For a current smoker, for example, whose probability of healing
is around 63% of the general population, the addition of Exogen
reduces expected cost by £1300–£1600 per patient. CONCLU-
SION: Between 8% and 9% more patients are likely to be healed
with Exogen after one year of treatment. For patients with a non-
union (deﬁned as a fracture which remains unhealed at 6
months), using Exogen before surgery (where possible and clin-
ically appropriate) is considered is expected to be a lower cost
option than immediate surgery. This approach is expected to
reduce cost by almost £3500 per patient, with no signiﬁcant
reduction in fracture healing. The funding for this study was pro-
vided by Smith & Nephew.
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HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH
BLUNT AND PENETRATING TRAUMA IN A UNITED STATES
MANAGED CARE POPULATION
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OBJECTIVE: Few studies have examined the direct economic
burden of traumatic injury. In this study, we estimated total per-
patient charges for healthcare resources consumed by patients
with blunt or penetrating trauma in a population of US managed
care organization (MCO) enrollees. METHODS: Retrospective
claims from the Ingenix MCO database were analyzed for
14,841 patients hospitalized for blunt or penetrating trauma
between 1/1/03 and 2/1/05. Study subjects had ≥6 months of
health plan enrollment prior to and following initial injury. Three
cohorts were identiﬁed based on published deﬁnitions for claims
data: isolated traumatic brain injury (TBI); other blunt or pene-
trating trauma with TBI; and other blunt or penetrating trauma
without TBI. Per-patient charges for all health care resources uti-
lized over a 6-month period following initial injury were esti-
mated. Baseline patient characteristics examined included mean
age and Injury Severity Score (ISS) at initial injury, as well as
mean Charlson Comorbidity Index (CCI) for the 6-month period
prior to initial injury. RESULTS: Among those with isolated TBI
(N = 3028, age = 38.17, ISS = 10.06, CCI = 0.69), mean per-
patient charges incurred during the index hospitalization were
$30,333; mean per-patient charges incurred during post-
discharge encounters were $4606 for subsequent hospitaliza-
tions, $764 for pharmaceuticals, and $7658 for outpatient and
other ancillary care. Among those with other trauma and TBI
(N = 2726, age = 37.53, ISS = 18.28, CCI = 0.44), these mean
charges were $101,189, $6018, $726, and $14,599, respectively.
Among those with other trauma but without TBI (N = 9087, age
= 50.09, ISS = 8.90, CCI = 1.08), these mean charges were
$42,509, $6443, $1102, and $10,952, respectively. CONCLU-
SION: Charges incurred during the index hospitalization were
39% higher among patients with both TBI and other trauma
compared to the other cohorts combined. When examining total
charges, the premium for combination trauma was >17%.
Results of this study illustrate and underscore the signiﬁcant
direct economic burden associated with combined systemic and
TBI injury.
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OBJECTIVES: To estimate the economic implications and health
beneﬁts of managing chronic osteoarthritis pain with once-daily
OROS® hydromorphone compared with ER oxycodone two or
three times a day from the perspective of German statutory
health insurance. METHODS: A discrete event simulation was
developed to follow a patient for a year from initiating oral
opioid treatment. The optimal morphine dose is assigned accord-
ing to the following base-case conversion ratios: hydromorphone
(1 : 5), oxycodone (1 : 2). At the end of a dose adjustment period,
patients can be satisﬁed or dissatisﬁed and stop medication. Pairs
of identical patients are created; one receives hydromorphone,
the other oxycodone; undergo dose adjustments, may suffer
adverse events, recurrence of pain, or discontinue. Dissatisﬁed
patients are prescribed other pain medications, steroid injections
or surgery. Utilities are assigned pre-treatment, updated until
reaching optimal dose, and when patient is non-compliant or dis-
satisﬁed. After one year, the quality-adjusted time and costs are
recorded. Distributions of pain relief sleep quality, satisfaction
and utilities are from clinical trial data. A pain specialist ensured
the simulation reﬂects the course of managing non-malignant
pain with opioids. Direct medical costs are in 2005 Euros. Sen-
sitivity analyses were conducted. RESULTS: Based on 100 repli-
cations of 1000 patient pairs over one year on a mean daily
morphine equivalent dose of 90 mg, 14% were dissatisﬁed.
Average time to optimal dose with oxycodone was 7.9 weeks,
approximately 3 weeks longer than hydromorphone. Costs per
patient were estimated at €1959 with oxycodone vs. €2101 with
hydromorphone. Hydromorphone was predicted to increase
QALYs by a mean 0.017 years per patient, resulting in ICER =
€8343/QALY gained. Sensitivity analyses revealed that results
were most sensitive to the conversion ratios, with hydromor-
phone (1 : 7.5) being dominant over oxycodone. CONCLU-
SIONS: Based on these analyses, OROS® hydromorphone is
expected to yield health beneﬁts at a reasonable cost in Germany.
